About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Officials say the collaboration will strengthen emergency response capabilities and ensure residents have continued access to ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

The medical use of artificial intelligence (AI) threatens to undermine patients' ability to make personalized decisions. New ...

Texas Attorney General Ken Paxton is seeking broad access to patient medical records as he battles a Dallas doctor under the ...

The Albany Med Health System and CDPHP announced last week the organizations have agreed on a new two-year contract which ...

Excessive waiting for appointments, for treatments to begin and for phone calls to be returned; a lack of coordination among ...

Allina Health System and other health care providers escaped a suit accusing them of sharing swaths of patients’ sensitive data without consent with third parties including Meta Platforms Inc.

Patients and their health care providers are saying it’s time Montana joined many other states in limiting how and when insurers can deny drugs or treatments through their preapproval process.